Shanghai Fires Two Scientists After 6-Year-Old Girl Died in Secret Gene-Editing Trial
An investigation found researchers hid troubling monkey test results and a child's death from regulators before a base-editing therapy proved fatal.
Shanghai authorities have fired two researchers and barred them from government-funded science for five years after an investigation found they concealed critical safety warnings before an experimental gene therapy killed a six-year-old girl, according to reporting this week from the South China Morning Post and other outlets.
The girl, referred to in coverage only as "Mei" to protect her identity, died in March 2025 after receiving an experimental base-editing therapy at Xinhua Hospital in Shanghai. The investigator-initiated trial was led by neuroscientist Zilong Qiu. Her death went largely unreported outside scientific circles until the journal Science and the watchdog site Retraction Watch exposed it in July 2026, more than a year later.
What the investigation found
Shanghai's investigation, announced this week, concluded that researchers failed to share concerning results from earlier monkey trials with the girl's doctors before she received the treatment. It also found they did not disclose her death in a paper the team published in February, and that they failed to clearly warn her family of the risk of death before the procedure went forward, according to coverage of the findings.
Two researchers were dismissed as a result, including the paper's first author, identified in reporting as Yang, and both were barred from applying for government science and technology funding for five years. Separately, reporting has indicated that Qiu and Yang accepted gifts and cash from the girl's family, though the exact amount is disputed across accounts. Shanghai officials said hospital-level penalties were also issued but did not specify what they were.
THEY DID NOT CLEARLY WARN THE FAMILY OF THE RISK OF DEATH
The case has become a flashpoint in the global debate over the ethics of fast-moving gene-editing research, particularly trials run outside the stricter oversight that governs most pharmaceutical-company-sponsored studies. Investigator-initiated trials like this one are typically subject to lighter regulatory scrutiny in China than company-sponsored drug trials, a gap that critics say allowed the risks here to go unchecked for too long.
In response, Shanghai said it would tighten oversight of high-risk cell and gene therapy trials going forward, though it has not detailed specific new rules. The case is likely to fuel renewed international scrutiny of base-editing research, a cutting-edge gene-therapy technique that has drawn billions in investment on the promise of correcting genetic diseases at the DNA level — and renewed questions about how thoroughly families are informed of the risks before enrolling children in experimental treatments with no guaranteed benefit.